AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now publicly funded in Ontario and are among the first therapies to receive ...
How public health became an endless battle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback